Thanks for the alert, but looks like yesterday was the day to get in. May be a little late to the party buying here.
plurka, that makes perfect sense. as any pharma trader knows, the next few weeks is where we get to feel the rush in regards to what we risk. i love that feeling.
I hear you. I think grabbing any ATHX shares sub $3, at this stage of the trials, is a good move. Of course, this is all IMHO.
He's one of those who straddles the fence and softly bashes by planting seeds of doubt. During these times when results are forthcoming, I try to avoid this message board because the BS is way to thick to wade through. However, it's like looking at the sun, I know I'm not supposed to, but curiosity eventually persuades me to take a quick peek.
Good luck to all longs.
Sentiment: Strong Buy
on a related note (if you have time) search 'Quants: The Alchemists of Wall Street' on youtube. it is a few years old, but still applies. really opens your eyes to the way the market really works.
so true. our society is so self centered and short sighted that many can't see what's coming. times like these i lay low and let the bears play their games, because it's only a matter of time before this one moves big. i just wish i had some extra funds laying around for this buying op.
Sentiment: Strong Buy
smart business move.
btw and not that it makes any difference, according to his bio on the Alliance site, he's still current Chairman. (Ex-Officio)
I think it's important to note the various references Gil makes in regards to regulatory committees and the FDA. Gil serves as chairman of the Alliance for Regenerative Medicine, and early on states the Alliance "is very focused on trying to educate regulatory and policy makers on how to create a more rational and efficient framework that will speed the development of these types of therapies."
Also, towards the end (around 01:09:00), Gil mentions how Athersys was proactive in their approach with the FDA to ensure they (the FDA) "define for us(Athersys) and with us, all of the studies you would like to see us run and we're not gonna stop 'til we cover every single dimension of this." He goes on further and is well worth the listen. Such a proactive approach seems to be a rarity nowadays.
I know these points have been discussed in the past, but I think they should be taken into serious consideration when anticipating the outcome of both the upcoming UC and stroke trial results.
Even though this video is over a year old, it still remains a key piece of DD. Athersys has a top notch management team IMHO.
I would surely welcome any positive Japan updates or new developments. Though, I'm not holding my breath for these conference presentations are pretty much boilerplate dog and pony. i'll still cross my fingers though.
a link to the article? it's in my orig post. just replace 'DOT' with an actual '.' Either yahoo doesn't allow links or i just don't know how to post them properly.
I thought so, too. Now, I'm not a big one for conspiracy theories and I surely don't think every negative move with the market is the illuminati exerting their control. However, just knowing that a share price can be influenced by big money/shorts makes it easier to weather the dips like ATHX just experienced. I think bio/pharm is even more susceptible to this type of MM influence, because of the idle time between Phase results, news releases, etc. Individual investors are much more protective of their hard earned $$'s, therefore, their emotions are easily tested.
Sentiment: Strong Buy
"Because Knowledge Is Power!" ~G.I. Joe
2:00 PM ET Feb 11, 2014
2014 BIO CEO & Investor Conference
Speaker: Dr. Gil Van Bokkelen, Chairman and CEO
I agree that institutions can hold a price down as well, stockvet. Why is so hard to believe that houses with big money don't keep a stock within a certain trading range in order to accumulate shares? When you see a large ask pop up, let's say 50,000 shares, you assume those are retail individual investors? Look into EDGX. It's not a conspiracy, it's a gray area of trading that the SEC should be prohibiting. To insinuate that someone is a basher or oblivious to the way the stock market works is ignorant if you ask me. I have always relied on my own DD and I have done just fine. I don't look to these message boards for solid advice, I use it as a springboard to research an insightful post's content a little deeper. If you choose not to believe that people are out there to take your money through less than savory tactics, then good luck and I praise your faith in an altruistic society. Good luck to all longs, because we are ALL in it to make some money.
FWIW...Taken from the Edison Initiation of Coverage Report dated oct 25, 2013
Exhibit 9: Athersys valuation model inputs and assumptions
MultiStem in ulcerative colitis (US + EU):
1.7m UC patients in US and EU; 10% addressable market (moderate-to-severe and refractory to available treatments); $15,000 effective annual cost of treatment; six years to peak sales; risk-adjusted milestones from Pfizer included ($2.5m on Phase II, $7.5m on successful Phase III, $25m on FDA approval)
MultiStem in ischaemic stroke (US):
800,000 annual incidence of stroke in US; 15% mortality rate; 85% ischaemic stroke; $20,000 effective annual cost of treatment; six years to peak sales
MultiStem in AMI (US):
700,000 annual incidence of AMI in US; 15% mortality rate; 75% receive PCI; $20,000 effective annual cost; six years to peak sales
MultiStem in GvHD (US):
25,000 allogeneic HSCTs in the US (projected rate); 50% develop GvHD; 50% refractory to steroids; $15,000 effective annual cost of treatment; six years to peak sales
Tried posting the link, but yahoo MB didn't let me post it..
Well said. Big money can by all means keep the price within a range in order to accumulate for the next move up. My last big long term hold was YM biosciences (YMI) and got in early at $.54. The price action of athx is quite similar to ymi when they were towards the end of their PH2 trial for nimutizinab(sp). They were acquired by Gilead soon after. I hope that's not the case here, because of the potential with multistem. I think the share price in a year would be much more than what the current purchase price would be.